Pharmaceutical company
Appears in 11 stories
GLP-1 market leader facing growing competition and declining sales forecasts
Kailera Therapeutics just pulled off the largest biotech initial public offering in history, raising $625 million and watching its shares surge 62.5% on the first day of trading. The company, founded less than two years ago with drugs licensed from a Chinese pharmaceutical firm, is now valued at roughly $3.5 billion — without a single approved product. That a startup built entirely around next-generation obesity drugs can command this kind of investor enthusiasm tells you where the pharmaceutical industry's center of gravity has shifted.
Updated 3 hours ago
First-mover in oral GLP-1 obesity pills, now facing direct competition
For two years, the most effective weight-loss drugs on the market required a weekly injection. That barrier is now falling. Eli Lilly began shipping Foundayo — the first oral GLP-1 weight-loss pill that can be taken any time of day without food or water restrictions — on April 6, 2026, just five days after the Food and Drug Administration (FDA) approved it in a record 50-day review. Priced at $149 per month for self-pay patients and as low as $25 with commercial insurance, Foundayo undercuts the list price of injectable alternatives by roughly 85%.
Updated Apr 6
Leads GLP-1 market with Wegovy injections and oral semaglutide ahead of Lilly's Foundayo entry
For patients who gained severe, uncontrollable weight after brain tumor surgery—often as children—there has never been an approved medication. That changed on March 19, 2026, when the Food and Drug Administration (FDA) approved Imcivree (setmelanotide) for acquired hypothalamic obesity, a condition affecting roughly 10,000 Americans whose damaged hypothalamus makes diet and exercise essentially useless. In clinical trials, patients lost 18.4% more body mass than those on placebo over one year. Two weeks later, on April 1, the FDA approved Eli Lilly's Foundayo (orforglipron), the first GLP-1 pill taken without food restrictions, achieving 12.4% weight loss.
Updated Apr 1
Manufacturer of Awiqli; planning US launch in second half of 2026
For 104 years, every insulin on the market has required at least one injection per day. On March 26, the Food and Drug Administration (FDA) approved Awiqli, a once-weekly basal insulin made by Novo Nordisk, for adults with type 2 diabetes — cutting the number of basal insulin injections from 365 to 52 per year.
Updated Mar 28
Manufacturer of Ozempic, Wegovy, and Saxenda; dominant GLP-1 market player
More than 30 million Americans now take GLP-1 receptor agonist drugs like Ozempic and Wegovy to lose weight. A persistent concern has dogged the medications since their rise: that they burn through muscle along with fat, leaving patients weaker even as they get thinner. A study published in Cell Reports Medicine in March 2026 found that while GLP-1 drugs do reduce lean body mass, the rate of muscle loss is not disproportionate to what occurs with diet and exercise alone — and crucially, patients' actual strength remained unchanged.
Market leader in GLP-1 obesity drugs; facing emerging competition
The biggest knock against today's blockbuster weight-loss drugs is that they burn muscle along with fat — up to 40% of the weight a patient loses on semaglutide can be lean tissue like muscle and bone. A new class of therapies now entering clinical trials attacks obesity through entirely different biology, targeting genes and metabolic pathways that strip fat while leaving muscle intact. On March 26, 2026, Wave Life Sciences reported that a single injection of its RNA-silencing drug WVE-007 cut visceral fat by 14.3% over six months while patients actually gained 2.4% lean mass — a profile no existing obesity drug can match.
Updated Mar 26
Manufacturer of semaglutide (Ozempic, Wegovy)
Drugs originally designed to control blood sugar and reduce weight may also protect the brain. A study of 95,490 people in Sweden, published in The Lancet Psychiatry on March 22, 2026, found that users of semaglutide—the compound in the blockbuster drugs Ozempic and Wegovy—experienced 42% fewer psychiatric hospitalizations, 44% less worsening depression, and 47% fewer substance-use-related crises compared to periods when they were not taking the drug.
Updated Mar 22
Patent holder defending market share against 40+ generic competitors in India
Only 200,000 of India's roughly 250 million people living with obesity have ever taken a GLP-1 receptor agonist—the class of drugs that includes Novo Nordisk's blockbuster Ozempic and Wegovy. On March 21, the day after Novo's last Indian patent expired, more than 40 companies began selling generic semaglutide at prices as low as 1,290 rupees a month—about $15, compared to $100-175 for the branded versions. It is the largest single-day generic launch in Indian pharmaceutical history.
Updated Mar 21
Maker of Ozempic and Wegovy; not pursuing dedicated addiction trials
Drugs designed to control blood sugar and shrink waistlines may also quiet the cravings that drive addiction. A study of more than 600,000 United States veterans, published March 4 in The BMJ, found that people taking GLP-1 medications were 14 percent less likely to develop a new substance use disorder and, if they already had one, experienced 50 percent fewer substance-related deaths and 39 percent fewer overdoses.
Updated Mar 6
Implementing additional insulin price cuts in 2026
On January 1, 2026, two unprecedented insulin programs launched simultaneously: nonprofit Civica Rx began distributing insulin glargine pens for $55 per box, while California became the first state to sell its own CalRx-branded insulin at the same price point—both undercutting branded products by up to 90%. The coordinated launches mark the first major breach in a pricing fortress built by three pharmaceutical giants who control 90% of the U.S. insulin market. Unlike existing insulin, these products require no insurance forms, no rebates, no hidden markups. Just one transparent price available to anyone.
Updated Feb 10
Launched first oral GLP-1 weight loss pill; negotiating BALANCE participation
Medicare has been banned from covering weight loss drugs since 2003. CMS launched the BALANCE voluntary model in December 2025 to work around the law—negotiating $50-per-month access to Ozempic, Wegovy, and similar blockbusters for 10% of Medicare enrollees starting July 2026. The workaround: don't call it weight loss coverage, call it treatment for chronic disease with specific comorbidities. Manufacturer applications closed January 8, 2026, with negotiations continuing through February 28.
Updated Jan 14
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
